Tickers

1. Composite Trajectory Verdict

For a pre-revenue clinical-stage biotechnology company, the cash flow statement and balance sheet (liquidity/runway) carry the most weight because operating losses are expected and the ability to fund ongoing development depends entirely on cash reserves and financing capacity.

Composite Trajectory: Mixed

Annual results show widening GAAP losses (net loss $21.2M in 2025 vs $14.9M in 2024) and higher operating cash burn ($10.7M vs $10.3M), reflecting advancing clinical programs (10-K 2025-12-31, Consolidated Statements of Operations; Consolidated Statements of Cash Flows). However, the company successfully raised $20.4M in financing during 2025 and $10.8M in H1 2026, maintaining a cash position above $43M through June 2026 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). Quarterly trends are mixed: Q1 2026 net loss narrowed slightly vs Q1 2025 ($7.2M vs $7.3M) while Q2 2026 widened ($6.6M vs $6.1M), and operating cash burn accelerated in H1 2026 ($13.6M) vs H1 2025 ($8.6M) (10-Q 2026-06-30, Consolidated Statements of Operations; Consolidated Statements of Cash Flows). The trajectory reflects expected clinical-stage spending increases offset by successful capital raises.

2. Red Flags

• Accelerating operating cash burn: Cash used in operating activities jumped to $13.6M in H1 2026 from $8.6M in H1 2025, a 58% increase, while net loss grew only 3% ($13.8M vs $13.4M), indicating working capital outflows (10-Q 2026-06-30, Consolidated Statements of Cash Flows).
• Rising accrued milestone liabilities: Accrued expenses include $2.0M for in-process R&D milestones (ARScience $0.7M, Methodist $0.1M, DRL $0.2M) as of June 2026, up from $1.1M at Dec 2025, reflecting upcoming cash obligations for achieved clinical milestones (10-Q 2026-06-30, Consolidated Balance Sheets; 10-K 2025-12-31, Consolidated Balance Sheets).
• Dependence on equity financing for runway: No credit facility exists; $10.8M of H1 2026 financing cash came from the January 2026 private placement, and the $30M ATM program had zero sales through June 2026 (10-Q 2026-06-30, MD&A Liquidity and Capital Resources; Consolidated Statements of Cash Flows).
• Collaboration revenue declining quarterly: R&D services revenue fell from $251K in Q1 2026 to $244K in Q2 2026, and no license/milestone revenue was recognized in H1 2026 after $8.4M in FY 2025 (10-Q 2026-03-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Annual net loss widened 43% to $21.2M in 2025 from $14.9M in 2024, driven by a 41% increase in R&D expenses ($16.7M vs $11.9M) as COYA 302 advanced to Phase 2, a 29% rise in G&A ($11.4M vs $8.9M), and $2.3M of in-process R&D charges for milestone payments vs $25K prior year (10-K 2025-12-31, Consolidated Statements of Operations). Collaboration revenue grew to $7.9M from $3.6M but remains entirely milestone-dependent. Quarterly comparisons show mixed but generally higher spend: Q2 2026 net loss ($6.6M) exceeded Q2 2025 ($6.1M) despite higher collaboration revenue ($244K vs $164K), while YTD 2026 net loss ($13.8M) exceeded YTD 2025 ($13.4M) (10-Q 2026-06-30, Consolidated Statements of Operations). R&D external clinical costs for COYA 302 ALS/FTD reached $6.3M in H1 2026 from zero in H1 2025, confirming the spending trajectory (10-Q 2026-06-30, MD&A Research and Development Expenses).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Operating cash burn increased annually to $10.7M in 2025 from $10.3M in 2024, and accelerated sharply to $13.6M in H1 2026 from $8.6M in H1 2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). The H1 2026 burn exceeded the net loss ($13.6M vs $13.8M) due to a $2.9M unfavorable change in operating assets/liabilities, primarily a $1.5M decline in accrued expenses and $0.6M increase in prepaids (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Financing cash inflows remained strong: $20.4M in FY 2025 (October 2025 offering) and $10.8M in H1 2026 (January 2026 private placement), but no ATM sales occurred in H1 2026 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). Net cash decreased $3.6M in H1 2026 after increasing $8.5M in FY 2025, leaving $43.2M at June 30, 2026 (10-Q 2026-06-30, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Cash and equivalents rose from $38.3M (Dec 2024) to $46.8M (Dec 2025) after the October 2025 offering, peaked at $50.7M (Mar 2026) after the January 2026 private placement, then declined to $43.2M (Jun 2026) as operating burn outpaced financing (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Total current assets followed a similar pattern: $44.3M → $49.9M → $53.3M → $47.1M. Current liabilities fell from $5.9M (Dec 2025) to $3.5M (Mar/Jun 2026) as accrued milestone payments were partially paid (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Accumulated deficit grew steadily: $40.7M (Dec 2024) → $62.0M (Dec 2025) → $69.2M (Mar 2026) → $75.8M (Jun 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Stockholders' equity increased from $39.6M to $43.3M over the period due to equity raises exceeding losses (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets).

6. Data Gaps

• Standalone Q3 2025 and Q4 2025 income statements and cash flows (only nine-month and full-year 2025 data provided in 10-K and 10-Q 2025-09-30)
• Q2 2024 quarterly income statement and cash flow details (only six-month 2024 data in 10-Q 2025-06-30)
• Detailed breakdown of "change in operating assets and liabilities" components for FY 2025 (only high-level description in MD&A)
• Terms and draw schedule for the $30M ATM facility beyond "no shares sold" through June 2026
• Specific maturity profile of any debt-like obligations (none reported, but license milestone payment schedules extend beyond 12 months)